Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
2017 · Blood · 1,419 citations
https://doi.org/10.1182/blood-2017-04-779405
C
Christophe Willekens
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
120
Papers
6.5K
Citations
28
h-index
45
i10-index
Christophe Willekens is an academic researcher from Université Paris-Saclay. The author has contributed to research in topics: Acute Myeloid Leukemia Research & Myeloproliferative Neoplasms: Diagnosis and Treatment & Histone Deacetylase Inhibitors Research. The author has an h-index of 28, co-authored 102 publications.
ORCID: 0000-0001-9814-8537Papers by this author
worksA miR-150/TET3 pathway regulates the generation of mouse and human non-classical monocyte subset
2018 · Nature Communications · 46 citations
https://doi.org/10.1038/s41467-018-07801-x
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients
2025 · Blood Cancer Journal · 22 citations
https://doi.org/10.1038/s41408-025-01269-x
Fulminant hemophagocytic lymphohistiocytosis induced by pandemic A (H1N1) influenza: a case report
2011 · Journal of Medical Case Reports · 20 citations
https://doi.org/10.1186/1752-1947-5-280
EE248 Cost-Effectiveness of Epigenetic Drugs in Oncology: A Systematic Review of Economic Evaluations
2025 · Value in Health · 0 citations
https://doi.org/10.1016/j.jval.2025.09.632
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat